Active, not recruitingPhase 2NCT06099782
A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)
Studying Small cell lung cancer
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Merck Sharp & Dohme LLC
- Principal Investigator
- Medical DirectorMerck Sharp & Dohme LLC
- Intervention
- Pembrolizumab (+) Berahyaluronidase alfa(biological)
- Enrollment
- 147 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2026
Study locations (30)
- Russell Medical ( Site 0160), Alexander City, Alabama, United States
- Alaska Oncology and Hematology ( Site 0121), Anchorage, Alaska, United States
- Highlands Oncology Group-Research Department ( Site 0133), Springdale, Arkansas, United States
- Marin Cancer Care ( Site 0148), Greenbrae, California, United States
- Holy Cross Hospital-Clinical Research ( Site 0159), Fort Lauderdale, Florida, United States
- Mid Florida Hematology and Oncology Center ( Site 0113), Orange City, Florida, United States
- Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research ( Site 0112), Marietta, Georgia, United States
- Kadlec Clinic Hematology and Oncology ( Site 0103), Kennewick, Washington, United States
- Instituto de Investigaciones Clínicas Mar del Plata ( Site 0300), Mar del Plata, Buenos Aires, Argentina
- Fundación Respirar ( Site 0302), Buenos Aires, Buenos Aires F.D., Argentina
- Instituto San Marcos ( Site 0305), San Juan, Argentina
- Port Macquarie - Mid North Coast Cancer Institute-Medical Oncology ( Site 1001), Port Macquarie, New South Wales, Australia
- Frankston Hospital-Oncology and Haematology ( Site 1007), Frankston, Victoria, Australia
- Clínica Puerto Montt ( Site 0404), Port Montt, Los Lagos Region, Chile
- FALP-UIDO ( Site 0401), Santiago, Region M. de Santiago, Chile
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06099782 on ClinicalTrials.govOther trials for Small cell lung cancer
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT06694454Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)National Cancer Institute (NCI)
- RECRUITINGNANCT07398599Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metastatic NSCLC: A Phase II StudySecond Affiliated Hospital of Nanchang University
- RECRUITINGPHASE1, PHASE2NCT07480213Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)Beijing Biotech
- RECRUITINGPHASE1, PHASE2NCT07227597A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)Merck Sharp & Dohme LLC
- RECRUITINGPHASE1NCT07348211First in Human Study of SIM0610 in Solid TumorsJiangsu Simcere Pharmaceutical Co., Ltd.
- RECRUITINGNANCT07161310Urolithin A in Patients With Previously Untreated Solid Tumors Receiving Immune Checkpoint InhibitorsGoethe University
- RECRUITINGPHASE2NCT07304739Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal MetastasesTianjin Medical University Cancer Institute and Hospital
- RECRUITINGPHASE1, PHASE2NCT06956690A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid TumorsHummingbird Bioscience